Baidu
map

J Med Genet:RIPOR2框内缺失是成年人听力损失发病的高频和高发原因

2020-07-26 AlexYang MedSci原创

听力损失是世界范围内最常见的残疾之一,对生活质量有着明显的影响。成年人听力损失发病是高度遗传的,但是遗传原因不清楚,且于儿童起始听力损失是不同的。

听力损失是世界范围内最常见的残疾之一,对生活质量有着明显的影响。成年人听力损失发病是高度遗传的,但是遗传原因不清楚,且与儿童起始听力损失是不同的。

最近,有研究人员进行了包括外显子测序和听力类型鉴定在内的家族和队列研究。研究发现,RIPOR2框内12个核苷酸缺失是成年人听力损失起始高发的一个原因,并且在12个家族中以常染色体显性性状分离。具有该框内缺失的63名受试者中表现出了不同的听力测定特征,且听力损失发病的平均年龄(SD)为30.6(14.9)岁(范围为0-70岁)。RIPOR2变异体在耳蜗毛细胞立体纤毛中定位异常,且不能恢复RIPOR2缺失毛细胞中的形态学缺陷,阐释了RIPOR 2变异体的功能。另外,引人注目的是,RIPOR2变异体在22952名个体中存在,且没有表现为听力损失。

最后,研究人员指出,他们的数据阐释了成年人听力损失起始的一个相对常见的遗传方式,并潜在的使得荷兰数千人处在听力损失风险。因此,RIPOR2是开发遗传治疗策略的一个很有吸引力的靶标。

原始出处:

Suzanne E de Bruijn, Jeroen J Smits, Chang Liu et al. A RIPOR2 in-frame deletion is a frequent and highly penetrant cause of adult-onset hearing loss. J Med Genet. 06 July 2020.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1734239, encodeId=3ae21e342392b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 18 03:19:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049313, encodeId=c0ea20493135a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Aug 15 04:19:30 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686344, encodeId=79b7168634499, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 23 12:19:30 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306538, encodeId=3d381306538e5, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510846, encodeId=75831510846e8, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610586, encodeId=02651610586e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2021-01-18 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1734239, encodeId=3ae21e342392b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 18 03:19:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049313, encodeId=c0ea20493135a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Aug 15 04:19:30 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686344, encodeId=79b7168634499, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 23 12:19:30 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306538, encodeId=3d381306538e5, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510846, encodeId=75831510846e8, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610586, encodeId=02651610586e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2020-08-15 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1734239, encodeId=3ae21e342392b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 18 03:19:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049313, encodeId=c0ea20493135a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Aug 15 04:19:30 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686344, encodeId=79b7168634499, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 23 12:19:30 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306538, encodeId=3d381306538e5, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510846, encodeId=75831510846e8, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610586, encodeId=02651610586e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1734239, encodeId=3ae21e342392b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 18 03:19:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049313, encodeId=c0ea20493135a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Aug 15 04:19:30 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686344, encodeId=79b7168634499, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 23 12:19:30 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306538, encodeId=3d381306538e5, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510846, encodeId=75831510846e8, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610586, encodeId=02651610586e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2020-07-28 ysjykql
  5. [GetPortalCommentsPageByObjectIdResponse(id=1734239, encodeId=3ae21e342392b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 18 03:19:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049313, encodeId=c0ea20493135a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Aug 15 04:19:30 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686344, encodeId=79b7168634499, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 23 12:19:30 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306538, encodeId=3d381306538e5, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510846, encodeId=75831510846e8, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610586, encodeId=02651610586e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2020-07-28 dzx0922892
  6. [GetPortalCommentsPageByObjectIdResponse(id=1734239, encodeId=3ae21e342392b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 18 03:19:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049313, encodeId=c0ea20493135a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Aug 15 04:19:30 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686344, encodeId=79b7168634499, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 23 12:19:30 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306538, encodeId=3d381306538e5, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510846, encodeId=75831510846e8, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610586, encodeId=02651610586e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 03:19:30 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

相关资讯

ELIFE:出生时携带越多的PTV,寿命缩短越多

从已有的双胞胎研究中可以看出,人类寿命的遗传性为23-33%。全基因组关联研究通过将特定等位基因与寿命特征联系起来,探讨了这个问题。

JAMA Psychiatry:遗传,而非环境因素是自闭症谱系障碍风险增加的主要原因

研究认为,随着时间的推移,自闭症谱系障碍和自闭症特征随环境因素变化的证据不足,遗传因素的作用始终大于环境因素。环境因素不能解释自闭症患病率的增加

J Clin Oncol:遗传性肾肿瘤的生长速率:积极监测和干预的意义

已经发表的积极监测的肾肿瘤生长速率中的大部分肿瘤均没有病理或者遗传数据。遗传性肾肿瘤的生长动力学仍旧不是很清楚。最近,有研究人员评估了遗传性肾肿瘤的生长速率以及与患者临床和遗传特性的相关性。研究共包括了292名患者,共453个遗传性肿瘤,包括了286个VHL缺陷性肿瘤、91个FLCN缺陷性肿瘤、52个MET缺陷性肿瘤和6个BAP1缺陷性肿瘤。研究发现,当使用遗传变异进行分层是,肿瘤生长速率(GR)

Environ Health:噪声峰度、NOX3遗传变异和生活方式与噪音诱导的听力损失相关性分析

噪音诱导的听力损失(NIHL)是一种复杂的疾病,由环境和遗传风险因素引起。最近,有研究人员探索了噪声峰度、NOX3遗传变异和生活方式与NIHL的相关性情况。研究是一个案例对照研究,包括了307名NIHL患者和307名匹配的对照。研究发现,那些暴露在复杂的噪音中的参与者比那些暴露在稳定的噪音中的参与者具有更高的NIHL风险(调整后OR=1.806, P=0.002)。在NOX3 rs12195525

Neurology:见于Leber遗传性视神经病的黑质T2高信号

29岁酗酒男性,表现为突发右眼进行性中心视力丧失。

Prostate:前列腺癌男性患者需求的定量分析

恶性前列腺癌(PCa)男性患者的指南最近有所变化,包括了遗传咨询(GC)和/或遗传测试(GT)。最近,有研究人员鉴定了PCa男性患者在GC之前和从GC中想获得的信息情况。研究的小组中包括了PCa男性患者,研究人员对交流进行了录音,并对与GT相关的主题、他们期望从健康护理者中想获得的信息以及与家庭成员有关的一些信息进行了分析。研究中共有37名PCa男性患者,共有7个焦点小组。研究发现,几乎所有的男性

Baidu
map
Baidu
map
Baidu
map